Polyol Precursor Assembly Inhibitor Development Service

Polyol Precursor Assembly Inhibitor Development Service

Polyol Precursor Assembly Inhibitor Development Service at CD BioGlyco

N-Glycosylation is an important flippase-mediated glycosyl transfer process involving the dolichol precursor assembly step. Long-chain isoprenol (dolichol) is synthesized in the endoplasmic reticulum membrane. Subsequently, glycosyl flippases transfer sugar residues from active sugar acylating agents (such as UDP sugars) to dolichol molecules, forming glycosylated dolichol precursor, which is further used by the enzyme system to synthesize different types of glycosylation products, such as glucose, mannose or N-acetylglucosamine. For the dolichol precursor assembly process in N-glycosylation, inhibitors are developed to interfere with or reduce the progress of this process, thereby intervening in the pathological processes of related diseases and providing new solutions for disease research.

  • Enzyme inhibitors

CD BioGlyco targets the enzyme involved in dolichol precursor assembly and develops polyol precursor assembly inhibitors to interfere with its activity, thereby blocking the glycosyl transfer process. Such as polyol transferase inhibitors, dehydrogenase inhibitors, glycolic acid decarboxylase inhibitors, etc. These inhibitors interfere with or block the polyol pathway.

  • Substrate competitive inhibitors

CD BioGlyco designs and synthesizes molecules similar to substrates such as dolichol or UDP sugar, which compete with normal substrates to bind to the active site of the enzyme, thereby reducing the conversion of normal substrates.

  • Molecular antagonist

CD BioGlyco designs and synthesizes structurally similar but inactive compounds to bind to target enzymes or substrates and prevent the conversion of normal substrates, thereby inhibiting them.

  • RNA interference (RNAi)-based strategies

CD BioGlyco uses synthetic small interfering RNA (siRNA) or small ribonucleic acid to target specific gene expression, thereby reducing the expression levels of related enzymes and affecting the assembly of dolichol precursors.

Based on the above inhibitor development mechanism, we use computer-aided drug design (CADD) and chemical synthesis to develop high-quality polyol precursor assembly inhibitors. Moreover, we have one-stop Glycosylation Inhibitor Development solutions, and we evaluate the biological activity of the synthesized compounds and use appropriate cell models or in vitro enzyme reaction systems to determine their inhibitory effects on dolichol precursor assembly.

CD BioGlyco uses different inhibitor development mechanisms to provide specialized multiple types of polyol precursor assembly inhibitor development services.

CD BioGlyco develops potent GlcNAc-PP-dolichol inhibitors through chemical synthesis. Deoxynojirimycin and its derivatives are a class of compounds with GlcNAc-PP-dolichol inhibitory activity. They are enzyme inhibitors that affect the synthesis or transport of GlcNAc-PP-dolichol by interfering with the activity of specific enzymes.

GlcNAc2-PP-dolichol is an important glycoprotein synthesis intermediate present in cells. CD BioGlyco uses computer-aided design and high-throughput screening technology to develop compounds with potential inhibitory activity against GlcNAc2-PP-dolichol synthase or related glycosyltransferases. We also provide mature analytical identification and activity evaluation for the developed inhibitors.

Polyol precursor assembly inhibitor development service.Fig.1 Polyol precursor assembly inhibitor development service. (CD BioGlyco)


Technology: X-ray crystallographic analysis

Journal: Expert Opinion on Therapeutic Patents

IF: 6.714

Published: 2019

Results: The authors discussed recent advances in aldose reductase (ALR2) inhibitors. ALR2 was a key enzyme of the polyol pathway and a key promoter of inflammatory and cytotoxic conditions. The development of novel compounds that inhibit ALR2 represented an excellent drug target. Compounds that inhibit ALR2 must possess some key structural features that are essential for favorable interactions with the enzyme's active site. The catalytically active site of ALR2 was highly hydrophobic (Figure 2), and the boundaries of the cavity were aromatic residues and nonpolar residues. Therefore, ALR2 had an obvious orientation towards lipophilic substrates.

ALR2 catalytic binding site.Fig.2 ALR2 catalytic binding site. (Quattrini & La Motta, 2019)


  • Diabetes research: The polyol pathway plays a vital role in patients with diabetes. By inhibiting the conversion of polyol precursors into sugar alcohols, the accumulation of sugar alcohols in cells is reduced and cell damage is prevented. Therefore, the development of inhibitors targeting polyol precursors contributes to basic research on diabetes and its related complications.
  • Regulation of chronic inflammation: The polyol pathway plays a certain regulatory role in chronic inflammatory diseases. Inhibiting the metabolism of polyol precursors may help suppress inflammatory responses and reduce the development and symptoms of related diseases.
  • Research on other metabolic diseases: Abnormal accumulation of polyol precursors is related to the occurrence and progression of other metabolic diseases (such as liver disease, and metabolic syndrome). The development of inhibitors targeting polyol precursors intervenes in the development of related diseases and provides new drug strategies for disease research.


  • CD BioGlyco has powerful polyol precursor assembly inhibitor design and chemical synthesis capabilities, which design and synthesize candidate compounds with potential inhibitory activity and perform structural optimization to improve their potency and selectivity.
  • CD BioGlyco has extensive experience in bioactivity assessment and evaluates the inhibitory activity, toxicity, and specificity of candidate polyol precursor assembly inhibitors using appropriate cell models or in vitro enzymatic reaction systems.
  • CD BioGlyco has top-notch polyol precursor assembly inhibitor development technology, and we quickly deliver high-quality polyol precursor assembly inhibitors to our clients.

CD BioGlyco uses high-throughput screening methods and optimization processes to speed up the polyol precursor assembly inhibitor development cycle and provide clients with efficient polyol precursor assembly inhibitor development service. Please feel free to contact us if you would like to inquire about detailed development content.


  1. Jannapureddy, S.; et al. Aldose reductase: an emerging target for the development of interventions for diabetic cardiovascular complications. Frontiers in Endocrinology. 2021, 12: 636267.
  2. Quattrini, L.; La Motta, C. Aldose reductase inhibitors: 2013-present. Expert Opinion on Therapeutic Patents. 2019, 29(3): 199-213.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.